S
Scienture Holdings, Inc. (SCNX)
NCM – Real Time Price. Currency in USD
0.40
-0.01 (-1.46%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.40
-0.01 (-1.46%)
At close: May 12, 2026, 4:00 PM EDT
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
| Name | Position |
|---|---|
| Dr. Narasimhan Mani M.B.A., Ph.D. | President, Co-CEO & Director |
| Dr. Shankar Hariharan Ph.D. | Founder, Co-CEO & Executive Chairman |
| Mr. Rahul Surana M.B.A., Ph.D. | Executive VP & COO of Scienture LLC |
| Ms. Michele Rath | Senior VP & Chief Commercial Officer of Scienture LLC |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | form8-k.htm |
| 2026-05-01 | 8-K | form8-k.htm |
| 2026-04-30 | 10-K/A | form10-ka.htm |
| 2026-03-30 | 10-K | form10-k.htm |
| 2025-11-18 | 8-K | form8-k.htm |
| 2025-11-14 | 8-K | form8-k.htm |
| 2025-11-13 | 8-K | form8-k.htm |
| 2025-11-12 | 10-Q | form10-q.htm |
| 2025-10-30 | 8-K | form8-k.htm |
| 2025-10-24 | 8-K | form8-k.htm |